Navigation Links
Scientists from Granada find a potential treatment to prevent diabetes and obesity
Date:10/17/2008

nd analysed its behaviour and its effects on the metabolism".

Mark Febbraio, scientific director in the Baker Heart Research Institute and a member of the Advisory Scientific Committee of Vitagenes, points out that "we obtained surprising results. The exogenous administration of interleukin-6 improved insulin sensitivity and the absorption of glucose, essential for diabetics". In addition, according to Mesa, "interleukin-6 also increased the expression of important genes related to fats metabolism, such as PPAR and UCP2. This suggests that interleukin-6 could be involved in the metabolic control of body weight".

However, Vitagenes has also reported that this is a preliminary study carried out in animal models, and we need new studies in humans to establish definite conclusions, "although everything seems to indicate that the application in humans would be possible in the medium term. This could substantially improve the state of people with diabetes and obesity", points out Mesa.


'/>"/>

Contact: Jos Luis Mesa
jose.mesa@vitagenes.com
34-678-222-210
Universidad de Granada
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2
Other Biology Technology:Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy 2Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports 2